Our corporate and capital markets teams assisted the founder and major shareholder, Mr. Kenneth Mulvany, in advocating for new board appointments, and we are delighted with the positive outcome.

BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery blending science and technology with a focus on finding solutions for complex diseases, who design technology to enable scientists to better understand the development of disease mechanisms, discover novel drug targets and make decisions with greater confidence.